# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Charles Darwin (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI003-SYN-TD
- Date: 1849-04-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Bernard Ashworth, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Six-week follow-up: results, gastroenterology consultation the same day, and a treatment plan. **S**

## History of present illness

Mr. Darwin is a 40-year-old man evaluated six weeks ago for more than a year of episodes of nausea and repeated vomiting, who returns for his results and is seen by gastroenterology on the same day. His diary records three episodes since the first visit, each starting in the early morning or after a social evening, with half an hour to an hour of nausea, sweating, trembling hands, a racing heart, and a swimming head, then vomiting many times over 18 to 30 hours. He lay in a dark room and sipped water, and did not need emergency care. Between episodes he has wind and tires by the afternoon but does not vomit. His weight is steady. He confirmed again that he has never used cannabis and does not take long hot baths or showers during episodes. The blood and urine tests and ECG at the first visit were normal, the CT enterography two weeks later was normal, and the upper endoscopy two weeks ago was normal, with normal duodenal biopsies. **S**

| Element | Detail |
|---|---|
| Episodes | Three in six weeks, each 18 to 30 hours, with a half-hour to one-hour prodrome |
| Between episodes | Wind and fatigue; no vomiting |
| Cannabis | Never used; no compulsive hot bathing |
| Results | Blood tests, urinalysis, ECG, CT enterography, and upper endoscopy all normal |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Positive | Episodic vomiting; wind between episodes; no blood in vomit or stool; no nocturnal pain |
| Constitutional | Positive | Tired after episodes; weight steady |
| Cardiovascular | Positive | Racing heart only in the prodrome; no chest pain or fainting |
| Neurological | Negative | No migraine headaches, weakness, or visual loss; swimming head only in the prodrome |
| Psychiatric | Positive | Worry about episodes in company; no low mood most days; no thoughts of self-harm |

5 systems reviewed. **S**

## Current medications

- Amitriptyline 25 mg oral tablet, one tablet at bedtime **S**
- Sumatriptan 20 mg nasal spray, one spray at the first sign of an episode **S**
- Ondansetron 8 mg orally disintegrating tablet at the first sign of an episode **S**

## Allergies

- No known allergy **S**

## Objective

BP 116/72 mmHg; pulse 76 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 71.4 kg; BMI 21.3 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Physical examination

| System | Finding |
|---|---|
| General | Well between episodes; weight 71.4 kg |
| Cardiovascular | Regular rhythm at 76 per minute; blood pressure 116/72 mmHg, with no drop on standing |
| Abdomen | Soft, non-tender, no distension or succussion splash |
| Neurological | Cranial nerves and gait normal |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Cyclic vomiting syndrome, provisional** (R11.15). Gastroenterology confirms that he meets the Rome IV criteria: stereotyped episodes of acute vomiting lasting less than a week, many more than three in the past year and two in the past six months, at least a week apart, without vomiting between them. The work-up excludes obstruction, mucosal disease, pancreatitis, thyroid and adrenal disease, celiac disease, and metabolic causes, and he does not use cannabis. The diagnosis is clinical and recorded as provisional. With episodes every one to three weeks that stop his work, the disease is moderate to severe, and prophylaxis is advised. **S**
   - Start amitriptyline 25 mg at bedtime and raise it by 25 mg every two weeks by portal message to 75 mg (about 1 mg/kg), as gastroenterology advises.
   - Abortive plan: sumatriptan 20 mg nasal spray and ondansetron 8 mg dissolving tablet together at the first sign of the prodrome.
   - Emergency department letter with his diagnosis and an agreed treatment protocol, to carry with him.
   - Trigger plan: regular small meals, regular sleep, and planning around travel and social events.
   - Relaxation breathing taught today; cognitive behavioral therapy offered, and he will consider it.
   - ECG when the dose reaches 50 mg and again at 75 mg.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Self-management | Episode diary: number, length, and severity of episodes, prodrome, emergency visits, and missed work | Every visit | Completed today | Three episodes in six weeks, 18 to 30 hours each, none needing emergency care; diary to continue |
| Examination | Rome IV criteria and red flags (vomiting between episodes, weight loss, nocturnal pain, neurological signs, onset after 50) | At diagnosis and with any change in pattern | Completed today | Criteria met with gastroenterology; no red flags |
| Laboratory | Blood count, electrolytes and glucose, liver panel, lipase, urinalysis, TSH, cortisol, celiac serology | At diagnosis between episodes; repeat only for an atypical episode | Up to date | All normal six weeks ago, drawn between episodes, including lipase 32 U/L, TSH 1.6, morning cortisol 14.2, and tissue transglutaminase IgA 1.2 with normal total IgA; urine dipstick normal |
| Imaging | Upper endoscopy and small-bowel imaging (CT enterography) | Once at diagnosis | Completed today | CT enterography four weeks ago and upper endoscopy with duodenal biopsies two weeks ago reviewed: both normal |
| Imaging | Gastric emptying study | Not routine; only between episodes when gastroparesis is suspected | Not indicated | No fullness, early satiety, or vomiting between episodes to suggest gastroparesis |
| Medication safety | ECG with QTc on amitriptyline and ondansetron (below 450 ms in men) | Baseline, at about 50 mg during titration, and at the target dose | Up to date | Baseline QTc 412 ms six weeks ago; repeat at about 50 mg and at 75 mg |
| Medication safety | Amitriptyline tolerability: drowsiness, dry mouth, constipation, dizziness on standing, weight | Each visit on treatment | Completed today | Baseline before amitriptyline: weight 71.4 kg, no constipation, no dizziness on standing |
| Survey | Mood and thoughts of self-harm on a tricyclic (PHQ-9) | Each visit on treatment | Up to date | PHQ-9 6 six weeks ago with item 9 scored 0; no thoughts of self-harm today |
| Survey | Anxiety screen (GAD-7) | At diagnosis, then every three months | Up to date | GAD-7 8 six weeks ago; repeat at three months |
| Medication safety | Abortive plan: timing and response to sumatriptan nasal spray and ondansetron, and dose limits | Every visit | Completed today | Sumatriptan nasal spray and ondansetron dissolving tablets prescribed today, with timing, the one-repeat limit, and no more than six sprays a week explained |
| Self-management | Individualized emergency department protocol letter | At diagnosis; update with any change in treatment | Completed today | Letter written with gastroenterology: intravenous fluids with dextrose, intravenous ondansetron, lorazepam if needed, a dark quiet room, and sparing use of opioids |
| Self-management | Triggers: sleep, meals, travel, social stress, infections | Every visit | Completed today | Social evenings, travel, short sleep, and long gaps without food identified from the diary |
| Self-management | Cannabis and other substance use, and hot-bathing behavior (cannabinoid hyperemesis syndrome) | At diagnosis and yearly | Completed today | Never used cannabis; no hot-bathing behavior |
| Examination | Comorbidities: migraine, orthostatic and autonomic symptoms, sleep disorders | At diagnosis and yearly | Completed today | No migraine headaches; no dizziness on standing; sleep regular except during episodes |
| Medication safety | Mitochondrial supplements (coenzyme Q10, riboflavin) | Conditional; consider with a partial response | Not indicated | Discussed as a conditional option; he prefers to start with amitriptyline alone and add them only if the response is partial |
| Medication safety | Alternative prophylaxis (topiramate or aprepitant) | Only if amitriptyline fails or is not tolerated | Not indicated | First-line amitriptyline started today |
| Self-management | Relaxation training, meditation, or biofeedback; cognitive behavioral therapy offered | Ongoing | Completed today | Diaphragmatic breathing taught; cognitive behavioral therapy offered |
| Examination | Weight and hydration | Every visit | Completed today | 71.4 kg, steady; well hydrated |
| Referral | Gastroenterology consultation | At diagnosis, then as needed | Completed today | Seen today: Rome IV criteria met, provisional diagnosis, prophylaxis and abortive plan advised |

## Goal progress

- Complete the work-up between episodes (blood and urine tests, ECG, CT enterography, and upper endoscopy) before the six-week visit. Outcome by 1849-04-14: All tests normal; Rome IV criteria met; provisional diagnosis of cyclic vomiting syndrome at the consultation. **S**
- At least half as many episodes after three months at the target dose of prophylaxis. In progress; target 1849-09-08. **S**
- Carry the abortive medicines and the emergency department letter, and use them at the prodrome. In progress; target 1849-06-09. **S**
- QTc below 450 ms at the target amitriptyline dose. In progress; target 1849-06-09. **S**
- Practice relaxation breathing most days and lower the GAD-7 score by the six-month review. In progress; target 1849-09-08. **S**

## Medication changes

- Started: Amitriptyline 25 mg oral tablet, one tablet at bedtime **S**
- Started: Sumatriptan 20 mg nasal spray, one spray at the first sign of an episode **S**
- Started: Ondansetron 8 mg orally disintegrating tablet at the first sign of an episode **S**

## Guideline basis

- Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association (2019), American Neurogastroenterology and Motility Society and Cyclic Vomiting Syndrome Association (Neurogastroenterology & Motility)
- Anxiety Disorders in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Portal messages at two and four weeks for the dose increases. Three-month review with the ECG, diary, and anxiety and mood screens. **S**
- Next scheduled visit 1849-06-09: three-month review: amitriptyline at target dose, ECG, episode diary, and anxiety screen. **S**
